Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Prostate Cancer
100%
T Cell Immunotherapy
100%
Mucin 1 (MUC1)
100%
Anti-androgen Therapy
100%
Chimeric Antigen Receptor T Cells (CAR-T)
66%
T Cells
55%
Tumor
22%
Luteinizing Hormone
22%
Receptor Targets
11%
Conventional Treatment
11%
Genetic Engineering
11%
Adoptive Immunotherapy
11%
Target Antigen
11%
Tumor Cells
11%
Antitumor Effect
11%
Treatment Modalities
11%
Human Trials
11%
Adoptive Transfer
11%
Tumor Growth
11%
Tumor Antigen
11%
Loss-variants
11%
Antigen Loss
11%
Retroviral Vector
11%
Health Problems
11%
Human Prostate Cancer Cells
11%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
11%
Long-term Benefit
11%
Variable number of Tandem Repeats
11%
Vector Encoding
11%
Androgen Ablation Therapy
11%
Immune Escape
11%
Heterogeneous Expression
11%
Antiandrogen
11%
Attractive Alternatives
11%
Western World
11%
Medicine and Dentistry
Immunotherapy
100%
Prostate Cancer
100%
T Cell
100%
Chimeric Antigen Receptor
100%
Antiandrogen Therapy
100%
Neoplasm
50%
Diseases
16%
Clinical Trial
16%
Tumor Progression
16%
In Vitro
16%
Adoptive Immunotherapy
16%
Tumor Cell
16%
Androgen
16%
Cancer Cell
16%
Retrovirus Vector
16%
Adoptive Transfer
16%
Tumor Antigen
16%
Ablation Therapy
16%
Antiandrogen
16%
Gonadorelin Derivative
16%
Gonadorelin Antagonist
16%
Variable Number of Tandem Repeat
16%
Side Effect
16%
Treatment Modality
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Immunotherapy
100%
Chimeric Antigen Receptor
100%
Antiandrogen
100%
Neoplasm
66%
Clinical Trial
16%
Diseases
16%
Tumor Growth
16%
Androgen
16%
Tumor Antigen
16%
Retrovirus Vector
16%
Gonadorelin Derivative
16%
Gonadorelin Antagonist
16%
Side Effect
16%
Immunology and Microbiology
T Cell
100%
Immunotherapy
100%
Chimeric Antigen Receptor
100%
Adoptive Immunotherapy
16%
Cancer Cell
16%
Tumor Antigen
16%
Tumor Cell
16%
Retrovirus Vector
16%
Variable Number of Tandem Repeat
16%
Immune Escape
16%
In Vitro
16%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Chimeric Antigen Receptor
100%
Clinical Trial
16%
Cancer Cell
16%
Retrovirus Vector
16%
Tumor Progression
16%
Tumor Antigen
16%
Variable Number Tandem Repeat
16%
Gonadotropin-Releasing Hormone
16%